Susan Percy Ivy

Susan Percy Ivy

Auto-generated profile, based on publicly available information

Susan Percy Ivy

National Cancer Institute 14 , Investigational Drug Branch, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2015 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NTNaoko Takebe
Naoko Takebe
LMLucio Miele
Lucio Miele
PHPamela Jo Harris
Pamela Jo Harris
WJWoondong Jeong
Woondong Jeong
HBHideaki Bando
Hideaki Bando
SIS. Percy Ivy
S. Percy Ivy

8 September 2009 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
SIS. Percy Ivy
S. Percy Ivy
JWJeannette Y. Wick
Jeannette Y. Wick
BKBennett M. Kaufman
Bennett M. Kaufman

14 March 2010 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SIS. Percy Ivy
S. Percy Ivy
LSLillian L. Siu
Lillian L. Siu
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
LRLarry Rubinstein
Larry Rubinstein
The goals and objectives of phase 1 clinical trials are changing to include further evaluation of endpoints such as molecular targeted effects, in addition to dose-toxicity profile of the investigational agent. Because of these changes in focus, the National Cancer Institute and Investigational Drug Steering Committee's Task Force on Clinical Trial Design met to evaluate the most efficient ways to design and implement early clinical trials with novel therapeutics. Clinical approaches discussed included the conventional 3 + 3 cohort expansion phase 1 design, multi-institutional phase 1 studies, accelerated titration designs, continual reassessment methods, the study of specific target patient populations, and phase 0 studies. Each of these approaches uniquely contributes to some aspect of the phase 1 study, with all focused on dose and schedule determination, patient safety, and limited patient exposure to ineffective doses of investigational agent. The benefit of labor-intensive generation of preliminary biomarker evidence of target inhibition, as well as the value of molecular profiling of the study population, is considered. New drug development is expensive and the failure rate remains high. By identifying patient populations expected to respond to the study agent and tailoring the treatment with a novel drug, investigators will be one step closer to personalizing cancer treatment. The “fail early and fast” approach is acceptable if the appropriate patient population is evaluated in the phase 1 trial. The approaches outlined in this overview address the merits, advantages, disadvantages, and obstacles encountered during first in human studies. Clin Cancer Res; 16(6); 1726–36

10 June 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NTNaoko Takebe
Naoko Takebe
RWRonald Q Warren
Ronald Q Warren
SIS Percy Ivy
S Percy Ivy
Induction of epithelial-to-mesenchymal transition (EMT) in cancer stem cells (CSCs) can occur as the result of embryonic pathway signaling. Activation of Hedgehog (Hh), Wnt, Notch, or transforming growth factor-β leads to the upregulation of a group of transcriptional factors that drive EMT. This process leads to the transformation of adhesive, non-mobile, epithelial-like tumor cells into cells with a mobile, invasive phenotype. CSCs and the EMT process are currently being investigated for the role they play in driving metastatic tumor formation in breast cancer. Both are very closely associated with embryonic signaling pathways that stimulate self-renewal properties of CSCs and EMT-inducing transcription factors. Understanding these mechanisms and embryonic signaling pathways may lead to new opportunities for developing therapeutic agents to help prevent metastasis in breast cancer. In this review, we examine embryonic signaling pathways, CSCs, and factors affecting EMT.

14 June 2010 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NTNaoko Takebe
Naoko Takebe
SIS. Percy Ivy
S. Percy Ivy
Selectively targeting cancer stem cells (CSC) or tumor-initiating cells (TIC; from this point onward referred to as CSCs) with novel agents is a rapidly emerging field of oncology. Our knowledge of CSCs and their niche microenvironments remains a nascent field. CSC's critical dependence upon self-renewal makes these regulatory signaling pathways ripe for the development of experimental therapeutic agents. Investigational agents targeting the Notch, Hedgehog, and Wnt pathways are currently in late preclinical development stages, with some early phase 1-2 testing in human subjects. This series of articles will provide an overview and summary of the current state of knowledge of CSCs, their interactive microenvironment, and how they may serve as important targets for antitumor therapies. We also examine the scope and stage of development of early experimental agents that specifically target these highly conserved embryonic signaling pathways. Clin Cancer Res; 16(12); 3106–12. ©2010 AACR.

1 August 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
XPXavier Paoletti
Xavier Paoletti
CTChristophe Le Tourneau
Christophe Le Tourneau
JVJaap Verweij
Jaap Verweij
LSLillian L. Siu
Lillian L. Siu
LSLesley Seymour
Lesley Seymour
JSJean-Charles Soria
Jean-Charles Soria